ROANOKE, Va.--(BUSINESS WIRE)--OcuCure Therapeutics, Inc. is an ophthalmic pharmaceutical company developing novel treatments to prevent vision loss caused by back of the eye diseases. The Company has received $1.5 million in seed financing to advance its compounds, which have been formulated as a topical eye drop for both wet Age-related Macular Degeneration (AMD) treatment and dry AMD prophylaxis. The Company’s compounds also have potential applications for diabetic retinopathy and other back of the eye blinding diseases.
